Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Identification of non-mutated neoantigens presented by TAP-deficient tumors.

Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T.

J Exp Med. 2018 Aug 16. pii: jem.20180577. doi: 10.1084/jem.20180577. [Epub ahead of print]

PMID:
30115740
2.

Digital PCR-based T Cell Quantification Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.

de Lange M, Nell RJ, Lalai RN, Versluis M, Jordanova ES, Luyten GP, Jager MJ, van der Burg SH, Zoutman WH, van Hall T, van der Velden PA.

Mol Cancer Res. 2018 Aug 9. pii: molcanres.0114.2018. doi: 10.1158/1541-7786.MCR-18-0114. [Epub ahead of print]

PMID:
30093564
3.

Identification of tumor antigens among the HLA peptidomes of Glioblastoma tumors and plasma.

Shraibman B, Barnea E, Melamed Kadosh D, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, Von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2018 Aug 2. pii: mcp.RA118.000792. doi: 10.1074/mcp.RA118.000792. [Epub ahead of print]

4.

The Effect of Productive HPV16 Infection on Global Gene Expression of Cervical Epithelium.

Kang SD, Chatterjee S, Alam S, Salzberg AC, Milici J, van der Burg SH, Meyers C.

J Virol. 2018 Jul 25. pii: JVI.01261-18. doi: 10.1128/JVI.01261-18. [Epub ahead of print]

PMID:
30045992
5.

Correlates of immune and clinical activity of novel cancer vaccines.

van der Burg SH.

Semin Immunol. 2018 Apr 27. pii: S1044-5323(18)30007-1. doi: 10.1016/j.smim.2018.04.001. [Epub ahead of print] Review.

6.

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

Bidmon N, Kind S, Welters MJP, Joseph-Pietras D, Laske K, Maurer D, Hadrup SR, Schreibelt G, Rae R, Sahin U, Gouttefangeas C, Britten CM, van der Burg SH.

J Immunol Methods. 2018 Jul;458:74-82. doi: 10.1016/j.jim.2018.04.007. Epub 2018 Apr 21.

7.

Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections.

Panagioti E, Klenerman P, Lee LN, van der Burg SH, Arens R.

Front Immunol. 2018 Feb 16;9:276. doi: 10.3389/fimmu.2018.00276. eCollection 2018. Review.

8.

T Cells Engaging the Conserved MHC Class Ib Molecule Qa-1b with TAP-Independent Peptides Are Semi-Invariant Lymphocytes.

Doorduijn EM, Sluijter M, Querido BJ, Seidel UJE, Oliveira CC, van der Burg SH, van Hall T.

Front Immunol. 2018 Jan 25;9:60. doi: 10.3389/fimmu.2018.00060. eCollection 2018.

9.

T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.

Doorduijn EM, Sluijter M, Marijt KA, Querido BJ, van der Burg SH, van Hall T.

Oncoimmunology. 2017 Nov 20;7(3):e1382793. doi: 10.1080/2162402X.2017.1382793. eCollection 2018.

10.

The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.

de Groot AF, Appelman-Dijkstra NM, van der Burg SH, Kroep JR.

Cancer Treat Rev. 2018 Jan;62:18-28. doi: 10.1016/j.ctrv.2017.10.010. Epub 2017 Nov 2. Review.

11.

Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.

Welters MJP, Ma W, Santegoets SJAM, Goedemans R, Ehsan I, Jordanova ES, van Ham VJ, van Unen V, Koning F, van Egmond SI, Charoentong P, Trajanoski Z, van der Velden LA, van der Burg SH.

Clin Cancer Res. 2018 Feb 1;24(3):634-647. doi: 10.1158/1078-0432.CCR-17-2140. Epub 2017 Oct 10.

PMID:
29018052
12.

The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.

Verdegaal EME, van der Burg SH.

Front Immunol. 2017 Sep 11;8:1113. doi: 10.3389/fimmu.2017.01113. eCollection 2017.

13.

Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.

Dammeijer F, Lau SP, van Eijck CHJ, van der Burg SH, Aerts JGJV.

Cytokine Growth Factor Rev. 2017 Aug;36:5-15. doi: 10.1016/j.cytogfr.2017.06.011. Epub 2017 Jun 28. Review.

14.

CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy.

Doorduijn EM, Sluijter M, Salvatori DC, Silvestri S, Maas S, Arens R, Ossendorp F, van der Burg SH, van Hall T.

Cancer Immunol Res. 2017 Aug;5(8):642-653. doi: 10.1158/2326-6066.CIR-16-0334. Epub 2017 Jun 21.

15.

HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia.

Samuels S, Marijne Heeren A, Zijlmans HJMAA, Welters MJP, van den Berg JH, Philips D, Kvistborg P, Ehsan I, Scholl SME, Nuijen B, Schumacher TNM, van Beurden M, Jordanova ES, Haanen JBAG, van der Burg SH, Kenter GG.

Cancer Immunol Immunother. 2017 Sep;66(9):1163-1173. doi: 10.1007/s00262-017-2006-y. Epub 2017 Apr 27.

PMID:
28451790
16.

IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma.

Melief SM, Visser M, van der Burg SH, Verdegaal EME.

Cancer Immunol Immunother. 2017 Jul;66(7):913-926. doi: 10.1007/s00262-017-1995-x. Epub 2017 Apr 11.

17.

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Gezgin G, Dogrusöz M, van Essen TH, Kroes WGM, Luyten GPM, van der Velden PA, Walter V, Verdijk RM, van Hall T, van der Burg SH, Jager MJ.

Cancer Immunol Immunother. 2017 Jul;66(7):903-912. doi: 10.1007/s00262-017-1991-1. Epub 2017 Apr 8.

18.

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients.

van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, Samuels S, Kenter GG, Cohen AF, Melief CJ, Burggraaf J, van Poelgeest MI, van der Burg SH.

Oncoimmunology. 2016 Dec 23;6(2):e1267095. doi: 10.1080/2162402X.2016.1267095. eCollection 2017.

19.

The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization.

Koskimaa HM, Paaso A, Welters MJP, Grénman S, Syrjänen K, van der Burg SH, Syrjänen S.

Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1491-1503. doi: 10.1007/s10096-017-2958-z. Epub 2017 Mar 21.

20.

Control of immune escaped human papilloma virus is regained after therapeutic vaccination.

Ma W, Melief CJ, van der Burg SH.

Curr Opin Virol. 2017 Apr;23:16-22. doi: 10.1016/j.coviro.2017.02.005. Epub 2017 Mar 7. Review.

21.

Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4+ and CD8+ T Cell Responses against Mouse Cytomegalovirus Infection.

Panagioti E, Boon L, Arens R, van der Burg SH.

Front Immunol. 2017 Feb 20;8:144. doi: 10.3389/fimmu.2017.00144. eCollection 2017.

22.

Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer.

Talebian Yazdi M, Schinkelshoek MS, Loof NM, Taube C, Hiemstra PS, Welters MJ, van der Burg SH.

Oncoimmunology. 2016 Nov 8;5(12):e1255393. doi: 10.1080/2162402X.2016.1255393. eCollection 2016.

23.

Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.

Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM.

Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10.

24.

The identification of patients at high risk for recurrent disease after treatment for early-stage cervical cancer.

Van Meir H, du Burck IJ, de Kam ML, Welters MJP, van der Burg SH, Trimbos JBMZ, de Kroon CD, van Poelgeest MIE.

Eur J Gynaecol Oncol. 2017;38(1):25-32.

PMID:
29767860
25.

Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis.

Ma W, Tummers B, van Esch EM, Goedemans R, Melief CJ, Meyers C, Boer JM, van der Burg SH.

Front Immunol. 2016 Nov 22;7:496. eCollection 2016.

26.

The importance of correctly timing cancer immunotherapy.

Beyranvand Nejad E, Welters MJ, Arens R, van der Burg SH.

Expert Opin Biol Ther. 2017 Jan;17(1):87-103. Epub 2016 Nov 16. Review.

PMID:
27802061
27.

Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, Behjati S, Velds A, Hilkmann H, El Atmioui D, Visser M, Stratton MR, Haanen JB, Spits H, van der Burg SH, Schumacher TN.

Nat Med. 2016 Oct 6;22(10):1192. doi: 10.1038/nm1016-1192d. No abstract available.

PMID:
27711057
28.

The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection.

Panagioti E, Redeker A, van Duikeren S, Franken KL, Drijfhout JW, van der Burg SH, Arens R.

PLoS Pathog. 2016 Sep 16;12(9):e1005895. doi: 10.1371/journal.ppat.1005895. eCollection 2016 Sep.

29.

Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.

van Poelgeest MI, Visconti VV, Aghai Z, van Ham VJ, Heusinkveld M, Zandvliet ML, Valentijn AR, Goedemans R, van der Minne CE, Verdegaal EM, Trimbos JB, van der Burg SH, Welters MJ.

Cancer Immunol Immunother. 2016 Dec;65(12):1451-1463. Epub 2016 Sep 12.

30.

Monitoring of the Immune Dysfunction in Cancer Patients.

Santegoets SJ, Welters MJ, van der Burg SH.

Vaccines (Basel). 2016 Sep 2;4(3). pii: E29. doi: 10.3390/vaccines4030029. Review.

31.

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.

Beyranvand Nejad E, van der Sluis TC, van Duikeren S, Yagita H, Janssen GM, van Veelen PA, Melief CJ, van der Burg SH, Arens R.

Cancer Res. 2016 Oct 15;76(20):6017-6029. Epub 2016 Aug 28.

32.

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.

Zom GG, Welters MJ, Loof NM, Goedemans R, Lougheed S, Valentijn RR, Zandvliet ML, Meeuwenoord NJ, Melief CJ, de Gruijl TD, Van der Marel GA, Filippov DV, Ossendorp F, Van der Burg SH.

Oncotarget. 2016 Oct 11;7(41):67087-67100. doi: 10.18632/oncotarget.11512.

33.

Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Cao J, Heijkants RC, Jochemsen AG, Dogrusöz M, de Lange MJ, van der Velden PA, van der Burg SH, Jager MJ, Verdijk RM.

Oncotarget. 2016 Jul 22;8(35):58021-58036. doi: 10.18632/oncotarget.10770. eCollection 2017 Aug 29.

34.

Neoantigen landscape dynamics during human melanoma-T cell interactions.

Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, Haanen JB, Kapiteijn EH, Schumacher TN, van der Burg SH.

Nature. 2016 Aug 4;536(7614):91-5. Epub 2016 Jun 27.

PMID:
27350335
35.

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH.

Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307.

PMID:
27075626
36.

De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P.

Cancer Immunol Res. 2016 Apr;4(4):279-88. doi: 10.1158/2326-6066.CIR-16-0045. Review.

37.

Vaccines for established cancer: overcoming the challenges posed by immune evasion.

van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ.

Nat Rev Cancer. 2016 Apr;16(4):219-33. doi: 10.1038/nrc.2016.16. Epub 2016 Mar 11. Review.

PMID:
26965076
38.

Editorial overview: Tumour immunology: What's beyond today's success in tumor immunology.

van der Burg SH, Marincola F.

Curr Opin Immunol. 2016 Apr;39:viii-x. doi: 10.1016/j.coi.2016.02.002. Epub 2016 Feb 20. No abstract available.

39.

A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency.

Punt S, Dronkers EA, Welters MJ, Goedemans R, Koljenović S, Bloemena E, Snijders PJ, Gorter A, van der Burg SH, Baatenburg de Jong RJ, Jordanova ES.

Cancer Immunol Immunother. 2016 Apr;65(4):393-403. doi: 10.1007/s00262-016-1805-x. Epub 2016 Feb 22.

40.

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.

van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, Löwik MJ, Hamming IL, van Esch EM, Hellebrekers BW, van Beurden M, Schreuder HW, Kagie MJ, Trimbos JB, Fathers LM, Daemen T, Hollema H, Valentijn AR, Oostendorp J, Oude Elberink JH, Fleuren GJ, Bosse T, Kenter GG, Stijnen T, Nijman HW, Melief CJ, van der Burg SH.

Clin Cancer Res. 2016 May 15;22(10):2342-50. doi: 10.1158/1078-0432.CCR-15-2594. Epub 2016 Jan 26.

41.

TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.

Doorduijn EM, Sluijter M, Querido BJ, Oliveira CC, Achour A, Ossendorp F, van der Burg SH, van Hall T.

J Clin Invest. 2016 Feb;126(2):784-94. doi: 10.1172/JCI83671. Epub 2016 Jan 19.

42.

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study.

Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, Walter S.

Cancer Immunol Immunother. 2016 Feb;65(2):161-9. doi: 10.1007/s00262-015-1782-5. Epub 2016 Jan 4.

43.

The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.

Talebian Yazdi M, van Riet S, van Schadewijk A, Fiocco M, van Hall T, Taube C, Hiemstra PS, van der Burg SH.

Oncotarget. 2016 Jan 19;7(3):3477-88. doi: 10.18632/oncotarget.6506.

44.

Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative.

Koskimaa HM, Paaso A, Welters MJ, Grénman S, Syrjänen K, van der Burg SH, Syrjänen S.

J Transl Med. 2015 Nov 25;13:370. doi: 10.1186/s12967-015-0733-4.

45.

A framework for T cell assays.

Britten CM, van der Burg SH, Gouttefangeas C.

Oncotarget. 2015 Nov 3;6(34):35143-4. doi: 10.18632/oncotarget.6181. No abstract available.

46.

Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.

de Lange MJ, van Pelt SI, Versluis M, Jordanova ES, Kroes WG, Ruivenkamp C, van der Burg SH, Luyten GP, van Hall T, Jager MJ, van der Velden PA.

Oncotarget. 2015 Nov 10;6(35):37824-35. doi: 10.18632/oncotarget.5637.

47.

The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome.

Gorter A, Prins F, van Diepen M, Punt S, van der Burg SH.

J Transl Med. 2015 Sep 10;13:295. doi: 10.1186/s12967-015-0664-0.

48.

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH.

Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772.

49.

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR.

Ann Oncol. 2015 Oct;26(10):2141-9. doi: 10.1093/annonc/mdv309. Epub 2015 Jul 27.

PMID:
26216383
50.

Therapeutic cancer vaccines.

Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH.

J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. Review.

Supplemental Content

Loading ...
Support Center